July 22, 2026 · Mayo Clinic proceedings · DOI: 10.1016/j.mayocp.2026.07.014

Alcohol Use Following GLP-1 Receptor Agonist Therapy in the Cooper Center Longitudinal Study

Listen to this summary

The authors aimed to investigate the relationship between glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy and changes in alcohol consumption among outpatient adults. Their analysis revealed that participants on GLP-1RA experienced a significant reduction in weekly alcohol intake compared to a control group; however, this association diminished when accounting for weight loss. The findings suggest that the reduction in alcohol use may be linked to weight changes associated with GLP-1RA treatment.

Tamanna Basri, Stephanie J Shea, Adam Brantley, Rahul Tharoor, Julia Chavez, Mehvish Khan, William G Burton, David Leonard, Carolyn E Barlow, Kerem Shuval, Laura F DeFina, E Sherwood Brown

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play